07:00 , Mar 15, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Crystal structure of dihydropteroate synthase bound to sulfonamide antibiotics The crystal structure of dihydropteroate synthase bound to sulfonamide antibiotics...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Clinical News

Dacart: Phase III data

GlaxoSmithKline and partner Medicines for Malaria Venture discontinued development of Dacart to treat malaria after Phase III data showed that the compound significantly reduced hemoglobin levels in a subset of patients with glucose-6-phosphate dehydrogenase (G6PD)...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Clinical News

CDA: Phase III started

GSK started a double-blind, African Phase III trial in 1,395 patients to compare CDA to malaria drug Coartem artemether/lumefantrine from Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). GSK is developing CDA with the Medicines for...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Clinical News

CDA: Phase III started

GSK started a double-blind, African Phase III trial in 900 patients to compare CDA to GSK's Lapdap, a combination of chlorproguanil hydrochloride and dapsone. GSK is developing CDA with the Medicines for Malaria Venture (Geneva,...